TRAX Stock Forecast & Price Target

First Tracks is positioned favorably because ANB033’s anti-CD122 mechanism appears clinically differentiated and partially de-risked by multiple external readthroughs in celiac disease, eosinophilic esophagitis, and vitiligo, supporting a broad pipeline-in-a-product opportunity. The company’s own Phase 1b celiac data showed histologic and symptom benefits with no active-arm SAEs, severe AEs, or AE-related discontinuations, while the analyst raised 2040E risk-adjusted ANB033 sales to $3.4B and total risk-adjusted sales to $5.4B across CeD, EoE, and vitiligo. Further upside comes from upcoming catalysts in 4Q26, 1Q27, and 3Q27, plus the added financial flexibility from the $200M private placement, which helps support development of ANB033, ANB101, and rosnilimab.

First Tracks is burdened by high clinical and mechanistic risk across its pipeline, as rosnilimab, ANB033, and ANB101 all remain vulnerable to disappointing trial readouts, safety issues, or limited progress beyond Ph1. The company also faces meaningful competitive pressure and may struggle to find a partner for rosnilimab, which would reduce external validation and potential non-dilutive funding. With no cash flow yet, it could burn more cash than anticipated and be forced into financing that dilutes shareholders, while broad biotech uncertainty around regulatory and trial outcomes further weighs on the outlook.